Back to Search Start Over

Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer.

Authors :
Sen HAN
Xu MA
Jian FANG
Source :
Chinese Journal of Lung Cancer; Jul2020, Vol. 23 Issue 7, p609-614, 6p, 1 Diagram
Publication Year :
2020

Abstract

Mesenchymal-epithelial transition factor (MET) gene is an important tumor driver gene of non-small cell lung cancer (NSCLC). Drugs targeting MET 14 exon skipping mutation bring new hope to patients. MET inhibitors that are currently on the market or are about to be marketed include: crizotinib, cabozantinib, savolitinib and tepotinib. The objective response rate of MET inhibitors is high, and the safety is good. However, resistance of MET-tyrosine kinase inhibitor (TKI) is inevitable, so it is necessary to pay attention to the study of drug resistance mechanism. In addition, the combined use of hepatocyte growth factor (HGF)/MET inhibitors and other drugs may play an important role in inhibiting and reversing drug resistance. [ABSTRACT FROM AUTHOR]

Details

Language :
Chinese
ISSN :
10093419
Volume :
23
Issue :
7
Database :
Supplemental Index
Journal :
Chinese Journal of Lung Cancer
Publication Type :
Academic Journal
Accession number :
144787348
Full Text :
https://doi.org/10.3779/j.issn.1009-3419.2020.102.32